Literature DB >> 9826719

Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy.

M Nijhuis1, C A Boucher, P Schipper, T Leitner, R Schuurman, J Albert.   

Abstract

It has long been assumed that HIV-1 evolution is best described by deterministic evolutionary models because of the large population size. Recently, however, it was suggested that the effective population size (Ne) may be rather small, thereby allowing chance to influence evolution, a situation best described by a stochastic evolutionary model. To gain experimental evidence supporting one of the evolutionary models, we investigated whether the development of resistance to the protease inhibitor ritonavir affected the evolution of the env gene. Sequential serum samples from five patients treated with ritonavir were used for analysis of the protease gene and the V3 domain of the env gene. Multiple reverse transcription-PCR products were cloned, sequenced, and used to construct phylogenetic trees and to calculate the genetic variation and Ne. Genotypic resistance to ritonavir developed in all five patients, but each patient displayed a unique combination of mutations, indicating a stochastic element in the development of ritonavir resistance. Furthermore, development of resistance induced clear bottleneck effects in the env gene. The mean intrasample genetic variation, which ranged from 1.2% to 5.7% before treatment, decreased significantly (P < 0.025) during treatment. In agreement with these findings, Ne was estimated to be very small (500-15,000) compared with the total HIV-1 RNA copy number. This study combines three independent observations, strong population bottlenecking, small Ne, and selection of different combinations of protease-resistance mutations, all of which indicate that HIV-1 evolution is best described by a stochastic evolutionary model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826719      PMCID: PMC24392          DOI: 10.1073/pnas.95.24.14441

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

Authors:  C A Boucher; E O'Sullivan; J W Mulder; C Ramautarsing; P Kellam; G Darby; J M Lange; J Goudsmit; B A Larder
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

2.  Rapid and simple method for purification of nucleic acids.

Authors:  R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

Review 3.  Basic concepts in RNA virus evolution.

Authors:  E Domingo; C Escarmís; N Sevilla; A Moya; S F Elena; J Quer; I S Novella; J J Holland
Journal:  FASEB J       Date:  1996-06       Impact factor: 5.191

4.  Independent evolution of the env and pol genes of HIV-1 during zidovudine therapy.

Authors:  A J Brown; A Cleland
Journal:  AIDS       Date:  1996-09       Impact factor: 4.177

5.  Fitness of RNA virus decreased by Muller's ratchet.

Authors:  L Chao
Journal:  Nature       Date:  1990-11-29       Impact factor: 49.962

6.  Anti-CD4 therapy for AIDS suggested by mathematical models.

Authors:  R J De Boer; C A Boucher
Journal:  Proc Biol Sci       Date:  1996-07-22       Impact factor: 5.349

7.  Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients.

Authors:  L Ruiz; M Nijhuis; C Boucher; T Puig; A Bonjoch; J Martínez-Picado; S Marfil; D de Jong; D Burger; A Arnó; M Balagué; B Clotet
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-09-01

8.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.

Authors:  G Croteau; L Doyon; D Thibeault; G McKercher; L Pilote; D Lamarre
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

9.  Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.

Authors:  J H Condra; D J Holder; W A Schleif; O M Blahy; R M Danovich; L J Gabryelski; D J Graham; D Laird; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash; T Yang; J A Chodakewitz; P J Deutsch; R Y Leavitt; F E Massari; J W Mellors; K E Squires; R T Steigbigel; H Teppler; E A Emini
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

10.  Cellular and humoral immunity in various cohorts of male homosexuals in relation to infection with human immunodeficiency virus.

Authors:  M T Roos; F Miedema; J K Eeftinck Schattenkerk; F de Wolf; J Goudsmit; J M Lange; S A Danner; T A Out; P T Schellekens
Journal:  Neth J Med       Date:  1989-04       Impact factor: 1.422

View more
  55 in total

1.  Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans.

Authors:  L E Cowen; L M Kohn; J B Anderson
Journal:  J Bacteriol       Date:  2001-05       Impact factor: 3.490

2.  The molecular clock of HIV-1 unveiled through analysis of a known transmission history.

Authors:  T Leitner; J Albert
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

3.  Structure and temporal dynamics of populations within wheat streak mosaic virus isolates.

Authors:  J S Hall; R French; T J Morris; D C Stenger
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  Genetic drift and within-host metapopulation dynamics of HIV-1 infection.

Authors:  S D Frost; M J Dumaurier; S Wain-Hobson; A J Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

5.  Active and selective transcytosis of cell-free human immunodeficiency virus through a tight polarized monolayer of human endometrial cells.

Authors:  H Hocini; P Becquart; H Bouhlal; N Chomont; P Ancuta; M D Kazatchkine; L Bélec
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

6.  Antiretroviral Drug Resistance in HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

7.  Assessing the effects of human mixing patterns on human immunodeficiency virus-1 interhost phylogenetics through social network simulation.

Authors:  Steven M Goodreau
Journal:  Genetics       Date:  2006-04       Impact factor: 4.562

8.  Genetic bottlenecks reduce population variation in an experimental RNA virus population.

Authors:  Hongye Li; Marilyn J Roossinck
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

9.  Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques.

Authors:  Magdalena Magierowska; Flavien Bernardin; Seema Garg; Silvija Staprans; Michael D Miller; Koen K A Van Rompay; Eric L Delwart
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.

Authors:  Martin S King; Richard Rode; Isabelle Cohen-Codar; Vincent Calvez; Anne-Geneviève Marcelin; George J Hanna; Dale J Kempf
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.